Amylyx Pharmaceuticals Inc (AMLX) Stock Price, Quote & News

Company Profile

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fix...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 682 0917

Website: amylyx.com

Address:

43 Thorndike Street, Cambridge, United States

prismmarketview Dec. 5 at 6:25 PM

Amylyx Pharmaceuticals (NASDAQ: $AMLX) reports early Phase 1 LUMINA trial data: AMX0114 is well-tolerated in ALS patients with no treatment-related serious adverse events. Enrollment for cohort 2 to begin soon. https://prismmarketview.com/amylyx-pharmaceuticals-reports-positive-early-safety-data-for-amx0114-in-als-lumina-trial/

0 · Reply

LoveRetailFroth Dec. 5 at 2:18 PM

$RXRX $RXRX Great Morning 💎s ☕️ $SANA $AMLX I am holding for 12 months for $30 plus🚀

0 · Reply

ajmore Dec. 5 at 2:15 PM

$AMLX physicians involved see data encouraging. also tolerability and safety good. no adverse events. proceeding to cohort 2.

0 · Reply

ajmore Dec. 5 at 2:11 PM

$AMLX first cohort data from AMX0114 published.

0 · Reply

LoveRetailFroth Dec. 4 at 9:02 PM

$RXRX Great day! 💎s all 🚀 $SANA $AMLX

1 · Reply

LoveRetailFroth Dec. 4 at 3:52 PM

$RXRX I was talking to my physician daughter yesterday, about this $SANA & $AMLX She has never reciprocated more positively to my thoughts as she did,ever before -:) ☕️

0 · Reply

LoveRetailFroth Dec. 4 at 3:39 PM

$RXRX 3 💎 s Bound for $30 plus $SANA $AMLX

0 · Reply

LoveRetailFroth Dec. 4 at 2:08 PM

$RXRX Good Morning 💎 s ☕️ $AMLX $SANA $NEWH $VVPR

0 · Reply

LoveRetailFroth Dec. 3 at 1:26 PM

$RXRX Good Morning 💎 s ☕️ $AMLX $SANA $PLTR $PLTY

0 · Reply

LoveRetailFroth Dec. 2 at 2:55 PM

$RXRX Good Morning 💎 s ☕️ $AMLX $SANA $PLTR $PLTY

0 · Reply

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial

Dec 3, 2025, 7:53 PM EST - 2 days ago

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Dec 3, 2025, 9:45 AM EST - 2 days ago

With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance?

Nov 28, 2025, 6:40 PM EST - 7 days ago

HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Nov 17, 2025, 12:20 PM EST - 18 days ago

This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead

Nov 13, 2025, 2:40 PM EST - 22 days ago

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX

Nov 6, 2025, 2:06 PM EST - 4 weeks ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:00 AM EST - 4 weeks ago

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 9:00 AM EST - 4 weeks ago

Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

Oct 30, 2025, 9:00 AM EDT - 5 weeks ago

Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 27, 2025, 12:20 PM EDT - 5 weeks ago

Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 16, 2025, 4:40 PM EDT - 7 weeks ago

AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Amylyx Investors to Contact the Firm Regarding Ongoing Investigation into Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders

Sep 10, 2025, 12:06 AM EDT - 3 months ago

Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock

Sep 9, 2025, 4:01 PM EDT - 3 months ago

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

Sep 8, 2025, 9:01 PM EDT - 3 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 2, 2025, 6:14 PM EDT - 3 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 27, 2025, 7:28 AM EDT - 3 months ago

Amylyx to stop development of rare brain disorder drug after trial failure

Aug 27, 2025, 7:00 AM EDT - 3 months ago

Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

Aug 26, 2025, 9:00 AM EDT - 3 months ago

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 7, 2025, 10:35 PM EDT - 4 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 11:13 AM EDT - 4 months ago

Amylyx (AMLX) Q2 Net Loss Narrows 43%

Aug 7, 2025, 7:00 AM EDT - 4 months ago

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 9:00 AM EDT - 4 months ago

Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 21, 2025, 4:26 PM EDT - 4 months ago

Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential

Jul 14, 2025, 2:15 PM EDT - 5 months ago

Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery

Jul 13, 2025, 5:00 PM EDT - 5 months ago

Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

Jul 8, 2025, 7:00 AM EDT - 5 months ago

Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025

Jun 27, 2025, 7:56 AM EDT - 5 months ago

Why Shares in Amylyx Pharmaceuticals Soared This Week

Jun 24, 2025, 2:59 PM EDT - 5 months ago

Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market

Jun 17, 2025, 10:00 AM EDT - 6 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Jun 15, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation

Jun 12, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation

Jun 10, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out

Jun 8, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation

Jun 5, 2025, 10:00 AM EDT - 6 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 3, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation

Jun 3, 2025, 7:00 AM EDT - 6 months ago

Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis

Jun 1, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect

May 29, 2025, 10:05 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect

May 27, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Stockholders to Inquire about Securities Investigation

May 25, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation

May 22, 2025, 10:00 AM EDT - 7 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 21, 2025, 7:00 AM EDT - 7 months ago

Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 12, 2025, 7:00 AM EDT - 7 months ago

Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome

May 11, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out

May 10, 2025, 11:19 AM EDT - 7 months ago

Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2025 Earnings Call Transcript

May 8, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect

May 8, 2025, 7:00 AM EDT - 7 months ago

Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results

May 7, 2025, 8:00 AM EDT - 7 months ago

Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences

prismmarketview Dec. 5 at 6:25 PM

0 · Reply

LoveRetailFroth Dec. 5 at 2:18 PM

$RXRX $RXRX Great Morning 💎s ☕️ $SANA $AMLX I am holding for 12 months for $30 plus🚀

0 · Reply

ajmore Dec. 5 at 2:15 PM

$AMLX physicians involved see data encouraging. also tolerability and safety good. no adverse events. proceeding to cohort 2.

0 · Reply

ajmore Dec. 5 at 2:11 PM

$AMLX first cohort data from AMX0114 published.

0 · Reply

LoveRetailFroth Dec. 4 at 9:02 PM

$RXRX Great day! 💎s all 🚀 $SANA $AMLX

1 · Reply

LoveRetailFroth Dec. 4 at 3:52 PM

$RXRX I was talking to my physician daughter yesterday, about this $SANA & $AMLX She has never reciprocated more positively to my thoughts as she did,ever before -:) ☕️

0 · Reply

LoveRetailFroth Dec. 4 at 3:39 PM

$RXRX 3 💎 s Bound for $30 plus $SANA $AMLX

0 · Reply

LoveRetailFroth Dec. 4 at 2:08 PM

$RXRX Good Morning 💎 s ☕️ $AMLX $SANA $NEWH $VVPR

0 · Reply

LoveRetailFroth Dec. 3 at 1:26 PM

$RXRX Good Morning 💎 s ☕️ $AMLX $SANA $PLTR $PLTY

0 · Reply

LoveRetailFroth Dec. 2 at 2:55 PM

$RXRX Good Morning 💎 s ☕️ $AMLX $SANA $PLTR $PLTY

0 · Reply

ajmore Dec. 2 at 12:27 PM

$AMLX Fidelity filing on Dec 1st, increase position by 595,200 shares to 2.43 mln.

1 · Reply

ajmore Dec. 2 at 6:50 AM

$AMLX Dec 5-7 ALS/MND conference: Amylyx Pharmaceuticals is a sponsor of the event and has announced its intention to participate. The company expects to present early cohort data from its Phase 1 LUMINA clinical trial of AMX0114 in ALS at the symposium.

1 · Reply

ajmore Dec. 1 at 9:47 PM

$AMLX Dec 2nd presenting at Evercore, Dec 3rd presenting at Citi.

1 · Reply

ajmore Dec. 1 at 2:41 PM

$AMLX Just a reminder: presentation of first cohort from the AMX0114 trial is this week, could be tomorrow. The current analysts estimates are not assigning any revenue to AMX0114, good data, will be fantastic and could take us much higher. The important bit is that we are working on ailments that matter to everyone. Its a win win.

1 · Reply

LoveRetailFroth Dec. 1 at 2:37 PM

$RXRX Good Morning 💎 s☕️ $SANA $AMLX

1 · Reply

LoveRetailFroth Nov. 28 at 2:51 PM

$SANA Good Morning 💎 s ☕️ $RXRX $AMLX $NEWH $VVPR

0 · Reply

Joe_088 Nov. 28 at 9:24 AM

$AMLX 👉👉 $MBOT

0 · Reply

LoveRetailFroth Nov. 27 at 4:59 PM

$RXRX Good Morning ☕️ & Happy Thanksgiving folks! GOD bless you all with Health Wealth, Peace & Happiness. $SANA $AMLX $NEWH

0 · Reply

MichaelKTrades Nov. 26 at 9:37 PM

$AMLX Another biotech banger, classic cup and handle base, volume dry up at the pivot

0 · Reply

LoveRetailFroth Nov. 26 at 8:38 PM

$SANA $RXRX $AMLX $VVPR I have loaded up on these & cash in sometime in 2026. Multi Baggers🚀🥃

0 · Reply

LoveRetailFroth Nov. 26 at 8:06 PM

$AMLX Don’t forget my this 💎 🚀 $RXRX $SANA

0 · Reply

WycklyTrader Nov. 26 at 5:06 PM

$AMLX / $ANRO $GAP Fill $GME $PLUG : $ QNCX trend-reversal-base breakout momentum heading into 1Q2026 ph3 data announcement with multiple 'potential' gap fills.

0 · Reply

Market Cap	1.59B
Revenue (ttm)	87.37M
Net Income (ttm)	-301.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-345.36%
Debt to Equity Ratio	0.00

Volume	1,105,600
Avg Vol	1,645,252
Day's Range	N/A - N/A
Shares Out	109.82M
Stochastic %K	49%
Beta	-0.34
Analysts	Strong Sell
Price Target	$20.33